Harald Hampel, MD, PhD, MSc

Harald Hampel, MD, PhD, MSc

Nutley, New Jersey, United States
25K followers 500+ connections

Join to follow
University of Munich

About

I serve as Chief Medical Officer, Senior Vice President, Neurology, at Eisai, and as a…

Articles by Harald

Activity

Join now to see all activity

Experience

  • Eisai US Graphic

    Eisai US

    Nutley, New Jersey, United States

  • -

    Woodcliff Lake, New Jersey, USA

  • -

    Woodcliff Lake, New Jersey, USA

  • -

    Paris, France

  • -

    Frankfurt, Germany

  • -

    Dublin, Ireland

  • -

    Munich, Germany

  • -

    Munich Area, Germany

  • -

    Munich Area, Germany

  • -

    National Institutes of Health (NIH), Bethesda, Maryland, USA

  • -

    Munich Area, Germany

  • -

    Greater New York City Area

Education

  • University of Munich

  • -

    Activities and Societies: Department of Psychiatry, Department of Neurochemistry, University of Munich, Germany

  • -

    Elected Professorial Fellow and Magister Artium, M.A., of Trinity College, University of Dublin, Ireland. In accordance with the provision in chapter 5, section 7 of the statutes, I was elected to Professorial Fellow by Trinity College, University of Dublin, and traditionally announced by the 43rd Provost Professor John Hegarty on Trinity Monday, May 12th, 2008, from the steps of the famous Examination Hall. Trinity College Dublin was founded as a corporation consisting of the Provost, the…

    Elected Professorial Fellow and Magister Artium, M.A., of Trinity College, University of Dublin, Ireland. In accordance with the provision in chapter 5, section 7 of the statutes, I was elected to Professorial Fellow by Trinity College, University of Dublin, and traditionally announced by the 43rd Provost Professor John Hegarty on Trinity Monday, May 12th, 2008, from the steps of the famous Examination Hall. Trinity College Dublin was founded as a corporation consisting of the Provost, the Fellows and the Scholars. Scholarship or research achievement of a high order is the primary qualification for Fellowship, coupled with evidence of the candidate's contribution to the academic life of the College and an effective record in teaching.

  • -

    Master of Science, M.Sc. in Business Administration, Management and Operations (focus on Health Care).

  • -

    Awarded special educational program supported by the German Academic Scholarship Foundation (Studienstiftung des deutschen Volkes).

  • -

    Full University Academic Award/Stipend of the German Academic Scholarship Foundation (German: Studienstiftung des deutschen Volkes), Germany's largest, oldest and most prestigious scholarship foundation.

    In line with its statutes, it supports "the university education of young people who, on account of their exceptional academic talents and their personalities, can be expected to make an outstanding contribution to society as a whole". The Studienstiftung is non-political…

    Full University Academic Award/Stipend of the German Academic Scholarship Foundation (German: Studienstiftung des deutschen Volkes), Germany's largest, oldest and most prestigious scholarship foundation.

    In line with its statutes, it supports "the university education of young people who, on account of their exceptional academic talents and their personalities, can be expected to make an outstanding contribution to society as a whole". The Studienstiftung is non-political, non-denominational and ideologically independent. The selection process is extremely rigorous and only those students who show outstanding academic and personal promise are chosen. The Studienstiftung awards academic awards/scholarships to fewer than 0.5% of the best German students. It is often referred to as Germany's "secret elite university".

  • -

    Undergraduate program in History and Philosophy, Faculty of Humanities, Departments of Philosophy and History, University of Constance, Germany.

  • -

    Internship and voluntary medical service at the Department of Orthopedic Surgery, University of Munich, Germany, followed by several internships in abdominal, heart and thoracic surgery, surgical oncology and clinical oncology in several renowned university based departments.

  • -

    Academic Award/Scholarship of the Jung Foundation for Science and Research (Jung Stiftung für Wissenschaft und Forschung), Hamburg, Germany.

  • -

    Academic Award/Stipend of the Biomedical Sciences Exchange Program between North America and Europe (BMEP) (c/o The Mount Desert Island Biological Laboratory (MDI), Salsbury Cove, Maine, USA).

  • -

    Witten/Herdecke University (UW/H) is a private, nonprofit University based in Witten, Germany.
    UW/H was the first German private institution of higher education to receive accreditation as a University. Times Higher Education noted that the university was considered "an idealistic model for the future of German higher education". Today the University has succeeded in being recognized as one of Germany's few private universities considered 'Humboldtian' and as a role model in terms of course…

    Witten/Herdecke University (UW/H) is a private, nonprofit University based in Witten, Germany.
    UW/H was the first German private institution of higher education to receive accreditation as a University. Times Higher Education noted that the university was considered "an idealistic model for the future of German higher education". Today the University has succeeded in being recognized as one of Germany's few private universities considered 'Humboldtian' and as a role model in terms of course structures, integration of practical and theoretical training.

Volunteer Experience

  • Medical Student Volunteer

    Lady Willingdon Hospital, Manali, Himachal Pradesh, India

    - 1 year

    Disaster and Humanitarian Relief

    A fifty five bedded hospital in the foothills of the Indian Himalayas in Manali. We provided high quality medical service and care to the people of this region. We hoped to impact lives and be transformational agents through our lives and medical humanitarian service.

    Supported by an academic award/ stipend of the German Academic Scholarship Foundation (Studienstiftung des deutschen Volkes).

    http://www.manalihospital.com/

Publications

  • Dementia: The rising global tide of cognitive impairment

    Nature Reviews Neurology

    A new study suggests that the application of uniform diagnostic criteria for mild cognitive impairment (MCI) substantially reduces variation in MCI prevalence estimates. Refinement and harmonization of clinical and research criteria are essential milestones towards improved testing of therapeutic interventions aimed at curbing the epidemic of MCI and dementia.

    Other authors
    • Simone Lista
    See publication

  • Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease

    Nature Genetics

    We conducted a search for rare, functional variants altering susceptibility to Alzheimer's disease that exploited knowledge of common variants associated with the same disease. We found that loss-of-function variants in ABCA7 confer risk of Alzheimer's disease in Icelanders (odds ratio (OR) = 2.12, P = 2.2 × 10(-13)) and discovered that the association replicated in study groups from Europe and the United States (combined OR = 2.03, P = 6.8 × 10(-15)).

    Other authors
    • S Steinberg
    • H Stefansson
    • J Snaedal
    • K Stefansson
    See publication

  • Functional EEG Biomarker Battery for Early-Stage Prediction of Alzheimer's Disease in Asymptomatic-At-Risk Amyloid-Positive Elderly Individuals

    Alzheimer’s Association International Conference 2014

    Other authors

  • Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

    Lancet Neurology

    In the past 8 years, both the International Working Group (IWG) and the US National Institute on Aging-Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's disease (AD) that better define clinical phenotypes and integrate biomarkers into the diagnostic process, covering the full staging of the disease. This Position Paper considers the strengths and limitations of the IWG research diagnostic criteria and proposes advances to improve the diagnostic framework. On the…

    In the past 8 years, both the International Working Group (IWG) and the US National Institute on Aging-Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's disease (AD) that better define clinical phenotypes and integrate biomarkers into the diagnostic process, covering the full staging of the disease. This Position Paper considers the strengths and limitations of the IWG research diagnostic criteria and proposes advances to improve the diagnostic framework. On the basis of these refinements, the diagnosis of AD can be simplified, requiring the presence of an appropriate clinical AD phenotype (typical or atypical) and a pathophysiological biomarker consistent with the presence of Alzheimer's pathology. We propose that downstream topographical biomarkers of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease. This paper also elaborates on the specific diagnostic criteria for atypical forms of AD, for mixed AD, and for the preclinical states of AD.

    Other authors
    See publication

  • Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease

    Nature Reviews Drug Discovery

    Our long-term vision includes risk factor and biomarker monitoring of the ageing population,
    with the use of effective anti-amyloid (and perhaps neuroprotective) therapies that will succeed in quelling the Alzheimer’s disease epidemic. Recent trial results have been
    disappointing, but we find cause for optimism.

    Other authors
    • Pauls S Aisen
    • Bruno Vellas
    See publication

  • Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge

    Nature Reviews Neurology

    Whether dominantly inherited variants of Alzheimer disease (AD) and 'sporadic' forms exhibit similar pathophysiological and biomarker signatures remains unresolved. A landmark study has proposed a biomarker progression model of dominantly inherited AD, but a complex systems biology and physiology approach is required to translate these findings to sporadic disease.

    Other authors
    • Simone Lista
    See publication

  • Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia

    Trends in Neurosciences

    Alzheimer's disease (AD) is a progressive age-related neurodegenerative disease. At the time of clinical manifestation of dementia, significant irreversible brain damage is already present, rendering the diagnosis of AD at early stages of the disease an urgent prerequisite for therapeutic treatment to halt, or at least slow, disease progression. In this review, we discuss various neuroimaging measures that are proving to have potential value as biomarkers of AD pathology for the detection and…

    Alzheimer's disease (AD) is a progressive age-related neurodegenerative disease. At the time of clinical manifestation of dementia, significant irreversible brain damage is already present, rendering the diagnosis of AD at early stages of the disease an urgent prerequisite for therapeutic treatment to halt, or at least slow, disease progression. In this review, we discuss various neuroimaging measures that are proving to have potential value as biomarkers of AD pathology for the detection and prediction of AD before the onset of dementia. Recent studies that have identified AD-like structural and functional brain changes in elderly people who are cognitively within the normal range or who have mild cognitive impairment (MCI) are discussed. A dynamic sequence model of changes that occur in neuroimaging markers during the different disease stages is presented and the predictive value of multimodal neuroimaging for AD dementia is considered.

    Other authors
    See publication

  • Cognitive intervention in Alzheimer disease

    Nature Reviews Neurology

    Alzheimer disease (AD) is one of the most prevalent chronic medical conditions affecting the elderly population. The effectiveness of approved antidementia drugs, however, is limited-licensed AD medications provide only moderate relief of clinical symptoms. Cognitive intervention is a noninvasive therapy that could aid prevention and treatment of AD. Data suggest that specifically designed cognitive interventions could impart therapeutic benefits to patients with AD that are associated with…

    Alzheimer disease (AD) is one of the most prevalent chronic medical conditions affecting the elderly population. The effectiveness of approved antidementia drugs, however, is limited-licensed AD medications provide only moderate relief of clinical symptoms. Cognitive intervention is a noninvasive therapy that could aid prevention and treatment of AD. Data suggest that specifically designed cognitive interventions could impart therapeutic benefits to patients with AD that are associated with substantial biological changes within the brain. Moreover, evidence indicates that a combination of pharmacological and non-pharmacological interventions could provide greater relief of clinical symptoms than either intervention given alone. Functional and structural MRI studies have increased our understanding of the underlying neurobiological mechanisms of aging and neurodegeneration, but the use of neuroimaging to investigate the effect of cognitive intervention on the brain remains largely unexplored. This Review provides an overview of the use of cognitive intervention in the healthy elderly population and patients with AD, and summarizes emerging findings that provide evidence for the effectiveness of this approach. Finally, we present recommendations for future research on the use of cognitive interventions in AD and discuss potential effects of this therapy on disease modification.

    Other authors
    See publication

  • Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

    Nature Reviews Drug Discovery

    Advances in therapeutic strategies for Alzheimer's disease that lead to even small delays in onset and progression of the condition would significantly reduce the global burden of the disease. To effectively test compounds for Alzheimer's disease and bring therapy to individuals as early as possible there is an urgent need for collaboration between academic institutions, industry and regulatory organizations for the establishment of standards and networks for the identification and…

    Advances in therapeutic strategies for Alzheimer's disease that lead to even small delays in onset and progression of the condition would significantly reduce the global burden of the disease. To effectively test compounds for Alzheimer's disease and bring therapy to individuals as early as possible there is an urgent need for collaboration between academic institutions, industry and regulatory organizations for the establishment of standards and networks for the identification and qualification of biological marker candidates. Biomarkers are needed to monitor drug safety, to identify individuals who are most likely to respond to specific treatments, to stratify presymptomatic patients and to quantify the benefits of treatments. Biomarkers that achieve these characteristics should enable objective business decisions in portfolio management and facilitate regulatory approval of new therapies

    Other authors
    See publication

  • Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

    Nature Reviews Neurology

    Intense multidisciplinary research has provided detailed knowledge of the molecular pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new therapeutic strategies with putative disease-modifying effects. Several of the most promising approaches, such as amyloid-beta immunotherapy and secretase inhibition, are now being tested in clinical trials. Disease-modifying treatments might be at their most effective when initiated very early in the course of AD, before amyloid…

    Intense multidisciplinary research has provided detailed knowledge of the molecular pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new therapeutic strategies with putative disease-modifying effects. Several of the most promising approaches, such as amyloid-beta immunotherapy and secretase inhibition, are now being tested in clinical trials. Disease-modifying treatments might be at their most effective when initiated very early in the course of AD, before amyloid plaques and neurodegeneration become too widespread. Thus, biomarkers are needed that can detect AD in the predementia phase or, ideally, in presymptomatic individuals. In this Review, we present the rationales behind and the diagnostic performances of the core cerebrospinal fluid (CSF) biomarkers for AD, namely total tau, phosphorylated tau and the 42 amino acid form of amyloid-beta. These biomarkers reflect AD pathology, and are candidate markers for predicting future cognitive decline in healthy individuals and the progression to dementia in patients who are cognitively impaired. We also discuss emerging plasma and CSF biomarkers, and explore new proteomics-based strategies for identifying additional CSF markers. Furthermore, we outline the roles of CSF biomarkers in drug discovery and clinical trials, and provide perspectives on AD biomarker discovery and the validation of such markers for use in the clinic.

    Other authors
    See publication
Join now to see all publications

Patents

  • Method for diagnosis of dementias and neuroinflammatory diseases based on an increased level of procalcitonin in cerebrospinal fluid

    Issued US 10921330

    CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are…

    CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are drawn from a measured PCT immunoreactivity which is above a threshold value typical for healthy individuals.

    Other inventors
    See patent

  • In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative disorders

    Issued US 8916388

    In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference…

    In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference value, and conclusions are drawn concerning the presence of a neurodegenerative disorder in the person on the basis of the person-specific complex reference value found.

    Other inventors
    • Andreas Bergmann
    • Andrea Ernst
    See patent

  • In vitro procedure for diagnosis and early diagnosis of neurodegenerative diseases

    Issued US 8298784

    An in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurogenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the…

    An in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurogenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the determination of the analyte is performed directly and/or indirectly as the determination of a relevant co-peptide generated from a mutual propeptide, and is based upon the measured concentration of the determined analyte thus making it possible to form conclusions about a neurodegenerative disease or an early form typical of such a disease or the course of the disease and/or the success of the efforts to relieve or prevent the disease.

    Other inventors
    • Andreas Bergmann
    • Andrea Ernst
    See patent

  • Neurodegenerative Markers for Psychiatric Conditions

    Issued EU 20120196300

    The present invention relates to methods for detecting a psychiatric condition optionally associated with a depression comprising the steps of measuring the concentration of at least one in vivo degradation product of tryptophan. Further, the present invention relates to the use of said values as predictive markers for the detection of a psychiatric condition optionally associated with a depression and a kit containing means for detecting said values.

    Other inventors
    • Aye Mu Myint
    • Manfred Schawaller
    • Robert Verkerk
    • Markus Schwarz
    • Norbert Mueller
    See patent

  • IN VITRO METHOD FOR THE DIAGNOSIS AND EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS

    Issued US 20100035286

    In vitro method for the detection and early detection of, for the determination of the degree of severity of, and for the assessment of the course of and prognosis of neurodegenerative disorders, in which an immunodiagnostic determination method is used to determine the apolipoprotein C-1 (Apo C-1) immunoreactivity in a serum or plasma sample from a patient suffering from subjective or objectively verifiable cognitive disorders.

    Other inventors
    • Andreas Bergmann
    • Andrea Ernst
    See patent

  • In vitro method for the diagnosis of neurodegenerative diseases

    Issued US 7547553

    An in vitro method for the detection, determination of severity and monitoring and prognosis of neurodegenerative diseases is disclosed. The presence and/or concentration of the physiologically inactive proadrenomedullin (proADM) partial peptide, in particular, the midregional proADM partial peptide, is determined in a biological fluid of a patient who is suffering from a neurodegenerative disease or is suspected of having such a disease. Conclusions about the presence, course, severity or…

    An in vitro method for the detection, determination of severity and monitoring and prognosis of neurodegenerative diseases is disclosed. The presence and/or concentration of the physiologically inactive proadrenomedullin (proADM) partial peptide, in particular, the midregional proADM partial peptide, is determined in a biological fluid of a patient who is suffering from a neurodegenerative disease or is suspected of having such a disease. Conclusions about the presence, course, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the presence and/or concentration of the specific partial peptide in the biological sample.

    Other inventors
    • Andreas Bergmann
    • Andrea Ernst
    See patent

  • Neurodegenerative Markers for Psychiatric Conditions

    Issued EU 20080131921

    The present invention relates to methods for detecting a psychiatric condition optionally associated with a depression comprising the steps of measuring the concentration of at least one in vivo degradation product of tryptophan. Further, the present invention relates to the use of said values as predictive markers for the detection of a psychiatric condition optionally associated with a depression and a kit containing means for detecting said values.

    Other inventors
    • Aye Mu Myint
    • Manfred Schawaller
    • Robert Verkerk
    • Markus Schwarz
    • Norbert Mueller
    See patent

  • IN VITRO MULTIPARAMETER DETERMINATION METHOD FOR THE DIAGNOSIS AND EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS

    Issued US 20100062463

    In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference…

    In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference value, and conclusions are drawn concerning the presence of a neurodegenerative disorder in the person on the basis of the person-specific complex reference value found.

    Other inventors
    • Andreas Bergmann
    • Andrea Ernst
    See patent

  • In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases

    Issued EU 20090263822

    An in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurogenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the…

    An in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurogenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the determination of the analyte is performed directly and/or indirectly as the determination of a relevant co-peptide generated from a mutual propeptide, and is based upon the measured concentration of the determined analyte thus making it possible to form conclusions about a neurodegenerative disease or an early form typical of such a disease or the course of the disease and/or the success of the efforts to relieve or prevent the disease.

    Other inventors
    • Andreas Bergmann
    • Andrea Ernst
    See patent

  • In Vitro Method For the Diagnosis of Neurodegenerative Diseases

    Issued US 20080199966

    An in vitro method for the detection, determination of severity and monitoring and prognosis of neurodegenerative diseases is disclosed. The presence and/or concentration of the physiologically inactive proadrenomedullin (proADM) partial peptide, in particular, the midregional proADM partial peptide, is determined in a biological fluid of a patient who is suffering from a neurodegenerative disease or is suspected of having such a disease. Conclusions about the presence, course, severity or…

    An in vitro method for the detection, determination of severity and monitoring and prognosis of neurodegenerative diseases is disclosed. The presence and/or concentration of the physiologically inactive proadrenomedullin (proADM) partial peptide, in particular, the midregional proADM partial peptide, is determined in a biological fluid of a patient who is suffering from a neurodegenerative disease or is suspected of having such a disease. Conclusions about the presence, course, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the presence and/or concentration of the specific partial peptide in the biological sample.

    Other inventors
    • Andreas Bergmann
    • Andrea Ernst
    See patent

  • CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases

    Issued EU 20080206797

    CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are…

    CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are drawn from a measured PCT immunoreactivity which is above a threshold value typical for healthy individuals

    Other inventors
    • Andreas Bergmann
    • Andrea Ernst
    See patent

Honors & Awards

  • Top 1% Highly Cited Neuroscience Researcher in 2024

    Clarivate - Web of Science

    Each researcher selected has authored multiple Highly Cited Papers™ which rank in the top 1% by citations for their field(s) and publication year in the Web of Science™ over the past decade. However, citation activity is not the sole selection indicator. This list, based on citation activity is then refined using qualitative analysis and expert judgment as we observe for evidence of community-wide recognition from an international and wide-ranging network of citing authors.

    Of the…

    Each researcher selected has authored multiple Highly Cited Papers™ which rank in the top 1% by citations for their field(s) and publication year in the Web of Science™ over the past decade. However, citation activity is not the sole selection indicator. This list, based on citation activity is then refined using qualitative analysis and expert judgment as we observe for evidence of community-wide recognition from an international and wide-ranging network of citing authors.

    Of the world’s population of scientists, Highly Cited Researchers are 1 in 1,000.

  • Top 1% Highly Cited Neuroscience Researcher in 2023

    Clarivate - Web of Science

    Each researcher selected has authored multiple Highly Cited Papers™ which rank in the top 1% by citations for their field(s) and publication year in the Web of Science™ over the past decade. However, citation activity is not the sole selection indicator. This list, based on citation activity is then refined using qualitative analysis and expert judgment as we observe for evidence of community-wide recognition from an international and wide-ranging network of citing authors.

    Of the…

    Each researcher selected has authored multiple Highly Cited Papers™ which rank in the top 1% by citations for their field(s) and publication year in the Web of Science™ over the past decade. However, citation activity is not the sole selection indicator. This list, based on citation activity is then refined using qualitative analysis and expert judgment as we observe for evidence of community-wide recognition from an international and wide-ranging network of citing authors.

    Of the world’s population of scientists, Highly Cited Researchers are 1 in 1,000.

  • Top 1% Highly Cited Neuroscience Researcher in 2022

    Clarivate - Web of Science

    In recognition of exceptional research performance demonstrated by production of multiple highly cited papers that rank in the top 1% for field and year in Neuroscience and Behavior.

  • CEO Award

    -

    CEO Award 2022 for accomplishments in Clinical Development, Medical and Regulatory Affairs, Alzheimer's Disease and Brain Health (ADBH), awarded by Eisai's CEO Mr. Haruo Naito, on May 30st, 2023.

  • Expertscape World Expert in Alzheimer's Disease 2022

    Expertscape

    On World Alzheimer Day 2022, Expertscape ranked Dr. Harald Hampel among the top 7 Alzheimer's disease researchers globally, which means in the Top 0.003% of 182,647 published authors worldwide on Alzheimer Disease from 2012 through 2022 based on contributions to 187 articles on the topic.

  • Expertscape World Expert in Alzheimer Disease 2021

    Expertscape

    On World Alzheimer Day 2021, Expertscape ranked Dr. Harald Hampel among the top 5 Alzheimer researchers globally, which means in the Top 0.003% of 167,177 published authors worldwide on Alzheimer Disease from 2011 through 2021 based on contributions to 218 articles on the topic.

  • Expertscape World Expert in Alzheimer Disease 2020

    Expertscape

    On World Alzheimer Day 2020, Expertscape ranked Dr. Harald Hampel among the top 5 Alzheimer researchers globally, among published authors worldwide on Alzheimer Disease from 2011 through 2020 based on contributions to articles on the topic.

  • CEO Award

    Eisai

    CEO Award 2019 for accomplishments in Medical Affairs, Neurology Business Group, awarded by Eisai's CEO Mr. Haruo Naito, on May 21st, 2020.

  • AXA-Sorbonne University Excellence Chair on Alzheimer’s disease

    AXA Research Fund

    The AXA Chair is the premium funding and award scheme of the AXA Research Fund.

    It aims at:

    -Creating a dedicated full-time senior academic position in an institution
    -Supporting a significant acceleration in the development of a research field
    -Fostering a step-change in the career of the appointed AXA Professor

    Voicing Out the Silent Markers of Alzheimer’s

    https://www.axa-research.org/en/project/harald-hampel

    To meet the need for early diagnosis of…

    The AXA Chair is the premium funding and award scheme of the AXA Research Fund.

    It aims at:

    -Creating a dedicated full-time senior academic position in an institution
    -Supporting a significant acceleration in the development of a research field
    -Fostering a step-change in the career of the appointed AXA Professor

    Voicing Out the Silent Markers of Alzheimer’s

    https://www.axa-research.org/en/project/harald-hampel

    To meet the need for early diagnosis of Alzheimer’s from the beginning, the AXA - Sorbonne University Chair on Alzheimer’s has been created with the aim of developing and validating new biomarkers to increase diagnostic accuracy at the totally asymptomatic stage and to better assess drug efficacy. Hosted by the highly specialized Institute for Memory and Alzheimer’s Disease (IM2A) using the latest cutting-edge genetic, biochemical and neuroimaging technology available, the Chair will utilize the combined resources of several first-class scientific research teams in a rich variety of related research fields—from cognition to neuroimaging to genetics—working from bench to bedside. It will use quality and exhaustive cohorts of patients from all disease stages, managed through the IM2A infrastructure, which is a national reference center for several Alzheimer’s and neurodegeneration-related clinical research programs and a leading institution worldwide.
    The Chair and full university professorship will be permanently held by Prof. Harald Hampel, who is a word-leading researcher with vast expertise and reputation in neurology, psychiatry and cutting-edge neuroscience research. With 20 years of experience, he has successfully developed international research programs dedicated to Alzheimer’s diagnosis and therapeutic algorithms.

  • Katharina-Hardt-Foundation Award

    Katharina-Hardt-Foundation

  • Katharina-Hardt-Foundation Research Award

    Katharina-Hardt-Foundation

  • Professorial Fellowship Trinitiy College, University of Dublin, Ireland

    Trinitiy College, University of Dublin, Ireland

    In accordance with the provision in chapter 5, section 7 of the statutes, I was elected to Professorial Fellow by Trinity College, University of Dublin, and traditionally announced by the 43rd Provost Professor John Hegarty on Trinity Monday, May 12th, 2008, from the steps of the famous Examination Hall. Trinity College Dublin was founded as a corporation consisting of the Provost, the Fellows and the Scholars. Scholarship or research achievement of a high order is the primary qualification for…

    In accordance with the provision in chapter 5, section 7 of the statutes, I was elected to Professorial Fellow by Trinity College, University of Dublin, and traditionally announced by the 43rd Provost Professor John Hegarty on Trinity Monday, May 12th, 2008, from the steps of the famous Examination Hall. Trinity College Dublin was founded as a corporation consisting of the Provost, the Fellows and the Scholars. Scholarship or research achievement of a high order is the primary qualification for Fellowship, coupled with evidence of the candidate's contribution to the academic life of the College and an effective record in teaching.

  • Kraepelin-Alzheimer-Medal

    Department of Psychiatry, University of Munich

  • Alois Alzheimer Award

    University of Munich

  • German Brain Foundation Research Award

    German Brain Foundation (Hirnliga e.V.)

  • Bernhard-von-Gudden Award

    University of Munich

  • Scholarship Ernst Jung-Foundation for Science and Research

    Ernst Jung-Foundation for Science and Research (c/o Hamburg, Germany)

    1994 - 1996
    Post-doctoral Research Fellowship at the Laboratory of Neurosciences, National Institutes on Aging (NIA), National Institutes of Health (NIH), Bethesda, Md., USA

  • Scholarship Biomedical Sciences Exchange Program between North America and Europe (c/o The Mount Desert Island Biological Laboratory, Salsbury Cove, Maine, USA)

    Biomedical Sciences Exchange Program between North America and Europe (BMEP) (c/o The Mount Desert Island Biological Laboratory, Salsbury Cove, Maine, USA)

    Clinical and Research fellowship at Albert Einstein College of Medicine, Bronx, New York, USA

  • Scholarship German National Academic Foundation Scholarship (c/o Studienstiftung des Deutschen Volkes, Germany)

    German National Academic Foundation Scholarship (c/o Studienstiftung des Deutschen Volkes, Germany)

    Lady Willingdon Hospital, Manali, Himachal Pradesh, India
    A fifty five bedded hospital in the foothills of the Indian Himalayas in Manali. We provided high quality medical service and care to the people of this region. We hoped to impact lives and be transformational agents through our lives and medical humanitarian service.

    Supported by an academic award/ stipend of the German Academic Scholarship Foundation (Studienstiftung des deutschen…

    Lady Willingdon Hospital, Manali, Himachal Pradesh, India
    A fifty five bedded hospital in the foothills of the Indian Himalayas in Manali. We provided high quality medical service and care to the people of this region. We hoped to impact lives and be transformational agents through our lives and medical humanitarian service.

    Supported by an academic award/ stipend of the German Academic Scholarship Foundation (Studienstiftung des deutschen Volkes).

    http://www.manalihospital.com/

  • Scholarship German National Academic Foundation (c/o Studienstiftung des Deutschen Volkes, Germany)

    German National Academic Foundation Scholarship (c/o Studienstiftung des Deutschen Volkes, Germany)

    Columbia University, New York, New York, USA

  • Scholarship, German National Academic Foundation (c/o Studienstiftung des Deutschen Volkes, Germany)

    Studienstiftung des Deutschen Volkes, Germany

    1986 - 1993

  • Scholarship Witten-Herdecke University, School of Medicine, Germany

    Witten-Herdecke University, School of Medicine, Germany

    1986 - 1991

Test Scores

  • Hirsch-Factor (h-index)

    Score: 151

    Google Scholar

    https://scholar.google.com/citations?user=rx0w3eIAAAAJ&hl=en

Languages

  • German

    Native or bilingual proficiency

  • English

    Full professional proficiency

  • French

    Professional working proficiency

Organizations

  • Alzheimer's & Dementia - The Journal of the Alzheimer's Association

    Reviewing Editor

    - Present

    In 2005, the Alzheimer's Association founded and launched Alzheimer's & Dementia®: The Journal of the Alzheimer's Association, a monthly publication that shares diverse knowledge about Alzheimer's science with the global scientific community. A peer-reviewed journal, Alzheimer's & Dementia aims to bridge knowledge gaps separating traditional fields of dementia research by covering the entire spectrum from basic science to clinical trials and social and behavioral investigations, providing a…

    In 2005, the Alzheimer's Association founded and launched Alzheimer's & Dementia®: The Journal of the Alzheimer's Association, a monthly publication that shares diverse knowledge about Alzheimer's science with the global scientific community. A peer-reviewed journal, Alzheimer's & Dementia aims to bridge knowledge gaps separating traditional fields of dementia research by covering the entire spectrum from basic science to clinical trials and social and behavioral investigations, providing a forum for: Rapid communication of new findings and ideas. Disseminating knowledge necessary for optimal translation of research findings into practical application and interventions. Increasing knowledge in diverse disciplines to promote early detection, diagnosis and/or interventions. Identifying promising new directions of research. Providing the scientific impetus for new initiatives. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, the premier bibliographic database of the National Library of Medicine, part of the National Institutes of Health. Inclusion in this prominent database signals recognition of the journal's scientific merit and contribution to the field of Alzheimer's research. The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. https://www.alz.org/research/for_researchers/journals/alzheimers_dementia_journal

  • Alzheimer’s Association International Conference® (AAIC®)

    Scientific Program Committee Reviewer

    - Present

    Reviewer of scientific program of the Alzheimer’s Association International Conferences® (AAIC®), in Amsterdam, Netherlands, July 16-20, 2023, and in Vienna, July 27-31, 2025.

  • Chinese Academy of Sciences

    Member of external international scientific review committee

    - Present

  • Neurodegeneration Precision Medicine Initiative (NPMI)

    Member

    - Present

    https://npmiweb.net/ Precision Medicine is an emerging translational science paradigm related to the dimensional spectrum of health and disease, which aims to optimize the effectiveness of disease prevention and deploying time-sensitive detection/diagnosis and treatment strategies tailored to the individual’s specific clinical-genetic-biological characteristics, psycho-social environment, and lifestyle risk factors. Such a holistic healthcare approach is actionable only through deep…

    https://npmiweb.net/ Precision Medicine is an emerging translational science paradigm related to the dimensional spectrum of health and disease, which aims to optimize the effectiveness of disease prevention and deploying time-sensitive detection/diagnosis and treatment strategies tailored to the individual’s specific clinical-genetic-biological characteristics, psycho-social environment, and lifestyle risk factors. Such a holistic healthcare approach is actionable only through deep understanding of the clinical-biological trajectories of disease and the identification of at-risk population (i.e., genetic-biological clusters). Precision Medicine in Neurology hypothesizes that the individual’s unique genetic, biological, neurophysiological, cognitive reserve, and environmental factors account for the vulnerability-resilience to neurodegenerative diseases, clinical-biological trajectories of illness, and response to symptomatic and disease-modifying therapies. In Oncology, Precision Medicine-oriented approaches led to the development of successful risk stratification and screening tools alongside the more recent approval of genetic/molecular pathway(s)-based therapeutic interventions for different cancer typologies. This innovation has represented a paradigm shift in medicine. A biomarker-guided, brain systems-wise, and spatial multi-scales approach is needed to capture the biological and neurophysiological construct of neurodegenerative diseases in humans. Systems biology and systems neurophysiology hold the potential to untangle the spatial and temporal coordinates of neurodegenerative diseases across molecular-cellular pathways and brain structural/functional networks.

  • The Journal of Prevention of Alzheimer's Disease (JPAD)

    Editorial Board Member

    - Present

    The Journal of Prevention of Alzheimer’s Disease (JPAD) will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including: neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and heath economic outcomes. JPAD will publish also the meeting abstracts from Clinical Trial on Alzheimer Disease (CTAD) and will be…

    The Journal of Prevention of Alzheimer’s Disease (JPAD) will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including: neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and heath economic outcomes. JPAD will publish also the meeting abstracts from Clinical Trial on Alzheimer Disease (CTAD) and will be distributed both in paper and online version worldwide. We hope that JPAD with your contribution will play a role in the development of Alzheimer prevention. https://www.springer.com/journal/42414/

  • University of Science and Technology of China (USTC), Neurodegenerative Disorder Research Center (NDRC) and Institute on Aging and Brain Disorders (IABD)

    Scientific Committee Member

    - Present

    The University of Science and Technology of China is a public research university in Hefei, Anhui, China. Under direct leadership of the Chinese Academy of Sciences, the university is co-funded by the Academy, the Ministry of Education of China, and the Anhui Provincial Government. The University of Science and Technology of China (USTC) is a prominent university in China and enjoys an excellent reputation worldwide. It was established by the Chinese Academy of Sciences (CAS) in 1958 in…

    The University of Science and Technology of China is a public research university in Hefei, Anhui, China. Under direct leadership of the Chinese Academy of Sciences, the university is co-funded by the Academy, the Ministry of Education of China, and the Anhui Provincial Government. The University of Science and Technology of China (USTC) is a prominent university in China and enjoys an excellent reputation worldwide. It was established by the Chinese Academy of Sciences (CAS) in 1958 in Beijing, as a strategic action by the Chinese government, to meet China’s science and technology needs and increases the country’s international competitiveness. CAS integrated its resources with USTC, with the aim of educating top talent in cutting-edge, interdisciplinary science and technology. The establishment of USTC was hailed as “a great event in the history of education and science of China”. In 1970, USTC moved to its current location in Hefei, the capital of Anhui Province. The Neurodegenerative Disease Research Center (NDRC) at University of Science and Technology of China (USTC) (Director: Professor Yong Shen, PhD) is devoted to combining basic research on mechanisms of cognition and neuron functions in the healthy brain with brain disorders. Our discoveries are laying the foundation for better understanding and treatments of various brain disorders, including Alzheimer’s disease, Parkinson’s disease, Cerebral vascular disease. The translational research approaches take advantages of the basic science discoveries in brain disorders to translate advances in the laboratories efficiently and rapidly into diagnosis, technologies and therapies for patients, their families, their friends and their communities. The mission of the NDRC is to promote and accelerate the transfer of basic science discoveries to clinical medical practice. The NDRC creates and supports multidisciplinary programs that help bring the discoveries of the laboratory to clinical applications.

  • CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference

    Scientific Committee Member

    - Present

    The Clinical Trials on Alzheimer's Disease conference (CTAD) is a meeting focused entirely on Alzheimer’s Disease Therapeutic Trials with key leaders in Alzheimer Disease research from Industry and Academia getting together and forming partnerships with the objective of speeding the development of effective treatments to fight the disease. https://www.ctad-alzheimer.com/

  • University of Belgrade, Serbia, Faculty of Medicine, Department of Neurology

    Visiting Professor

    - Present

    The University of Belgrade is a public university in Serbia. It is the oldest and largest modern university in Serbia. Founded in 1808 as the Belgrade Higher School in revolutionary Serbia, by 1838 it merged with the Kragujevac-based departments into a single university. The Faculty of Medicine is a constituent institution of the University of Belgrade, which offers a wide range of academic courses in Serbian and English, including specialist practice within a network of hospitals, institutes…

    The University of Belgrade is a public university in Serbia. It is the oldest and largest modern university in Serbia. Founded in 1808 as the Belgrade Higher School in revolutionary Serbia, by 1838 it merged with the Kragujevac-based departments into a single university. The Faculty of Medicine is a constituent institution of the University of Belgrade, which offers a wide range of academic courses in Serbian and English, including specialist practice within a network of hospitals, institutes and medical clinics.

  • Trinity College, University of Dublin

    Professorial Fellow

    - Present

    In accordance with the provision in chapter 5, section 7 of the statutes, I was elected to Professorial Fellow by Trinity College, University of Dublin, and traditionally announced by the 43rd Provost Professor John Hegarty on Trinity Monday, May 12th, 2008, from the steps of the famous Examination Hall. Trinity College Dublin was founded as a corporation consisting of the Provost, the Fellows and the Scholars. Scholarship or research achievement of a high order is the primary qualification for…

    In accordance with the provision in chapter 5, section 7 of the statutes, I was elected to Professorial Fellow by Trinity College, University of Dublin, and traditionally announced by the 43rd Provost Professor John Hegarty on Trinity Monday, May 12th, 2008, from the steps of the famous Examination Hall. Trinity College Dublin was founded as a corporation consisting of the Provost, the Fellows and the Scholars. Scholarship or research achievement of a high order is the primary qualification for Fellowship, coupled with evidence of the candidate's contribution to the academic life of the College and an effective record in teaching.

  • Alzheimer's & Dementia - The Journal of the Alzheimer's Association

    Senior Associate Editor

    -

    In 2005, the Alzheimer's Association founded and launched Alzheimer's & Dementia®: The Journal of the Alzheimer's Association, a monthly publication that shares diverse knowledge about Alzheimer's science with the global scientific community. A peer-reviewed journal, Alzheimer's & Dementia aims to bridge knowledge gaps separating traditional fields of dementia research by covering the entire spectrum from basic science to clinical trials and social and behavioral investigations, providing a…

    In 2005, the Alzheimer's Association founded and launched Alzheimer's & Dementia®: The Journal of the Alzheimer's Association, a monthly publication that shares diverse knowledge about Alzheimer's science with the global scientific community. A peer-reviewed journal, Alzheimer's & Dementia aims to bridge knowledge gaps separating traditional fields of dementia research by covering the entire spectrum from basic science to clinical trials and social and behavioral investigations, providing a forum for: Rapid communication of new findings and ideas. Disseminating knowledge necessary for optimal translation of research findings into practical application and interventions. Increasing knowledge in diverse disciplines to promote early detection, diagnosis and/or interventions. Identifying promising new directions of research. Providing the scientific impetus for new initiatives. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, the premier bibliographic database of the National Library of Medicine, part of the National Institutes of Health. Inclusion in this prominent database signals recognition of the journal's scientific merit and contribution to the field of Alzheimer's research. https://www.alz.org/research/for_researchers/journals/alzheimers_dementia_journal

  • Alzheimer Precision Medicine Initiative (APMI)

    Founding President and Principal Investigator

    -

    Precision medicine (PM) is an evolving scientific renaissance movement implementing key breakthrough technological and scientific advances to overcome the limitations of traditional symptom- and sign-based phenotypic diagnoses and clinical “one-size-fits-all, magic bullet drug development” in these largely heterogeneous target populations. It is a conceptual shift from ineffective treatments for biologically heterogeneous “population averages” to individually-tailored biomarker guided targeted…

    Precision medicine (PM) is an evolving scientific renaissance movement implementing key breakthrough technological and scientific advances to overcome the limitations of traditional symptom- and sign-based phenotypic diagnoses and clinical “one-size-fits-all, magic bullet drug development” in these largely heterogeneous target populations. It is a conceptual shift from ineffective treatments for biologically heterogeneous “population averages” to individually-tailored biomarker guided targeted therapies. PM is defining which therapeutic approach will be the most effective for a specific individual, at a determined disease stage, across multiple medical research fields, including neuroscience, neurology and psychiatry. The launch of the Alzheimer Precision Medicine Initiative (APMI) and its associated cohort program in 2016—facilitated by the academic core coordinating center run by the Sorbonne University Clinical Research Group in Alzheimer Precision Medicine (Sorbonne University GRC n°21 APM)”—is geared at transforming healthcare, conventional clinical diagnostics, and drug development research in Alzheimer’s disease. Ever since the commencement of the APMI, the international interdisciplinary research network has introduced groundbreaking translational neuroscience programs on the basis of agnostic exploratory genomics, systems biology, and systems neurophysiology applying innovative “big data science”, including breakthrough artificial intelligence-based algorithms. Here, we present the scientific breakthrough advances and the pillars of the theoretical and conceptual development leading to the APMI.

  • 6th Hospital of Peking University and the City Key Laboratory of Dementia Translational Medicine

    Member of the academic committee

    -

    Faculty of Medicine

  • Trinity College, University of Dublin, Ireland

    Adjunct Professor

    -

    Appointment by Trinity College, University of Dublin, Faculty of Medicine, Department and Discipline of Psychiatry

  • University of Munich, Germany

    Visiting Professor

    -

    Faculty of Medicine, Department of Psychiatry

  • Munich Center for Neurosciences - Brain & Mind - Graduate School of Systemic Neuroscience

    Faculty Member

    -

    The Munich Center for Neurosciences – Brain & Mind (MCN) was founded in 2005 to create a local network in and around Munich that connects all groups and disciplines with interests related to questions of neurobiology, cognition, and “brain & mind”. The center provides a platform for interdisciplinary interactions, supports the establishment of new collaborative research programs and has developed a teaching concept that attracts excellent students at all levels of training. The program M.Sc…

    The Munich Center for Neurosciences – Brain & Mind (MCN) was founded in 2005 to create a local network in and around Munich that connects all groups and disciplines with interests related to questions of neurobiology, cognition, and “brain & mind”. The center provides a platform for interdisciplinary interactions, supports the establishment of new collaborative research programs and has developed a teaching concept that attracts excellent students at all levels of training. The program M.Sc. Neurosciences was initiated and generously funded within the framework of the Elite Network of Bavaria, and the Graduate School of Systemic Neurosciences Ph.D. program, founded via the German Excellence Initiative. Both teaching entities were fundamentally inspired by the MCN Teaching Concept. Also research consortia like the SFB 870: Assembly and Function of Neuronal Circuits in Sensory Processing, a Collaborative Research Center resulted from scientific interactions of many members of the MCN, plus several other research and training networks such as the Bernstein Center for Computational Neuroscience (BCCN) Munich. The SFB 870 very successfully facilitated research for 13 years and ended in 2022 after reaching its maximally extended end of funding period III. Furthermore, several Research Training Groups, e.g. 1091 Orientation & Motion in Space and 2175 'Perception in Context and its Neural Basis' had profited greatly from established networks within MCN and its teaching concept. This only begins to exemplify how MCN fosters the city of Munich as an internationally attractive site for training and research in neurosciences.

Recommendations received

2 people have recommended Harald

Join now to view

More activity by Harald

View Harald’s full profile

  • See who you know in common
  • Get introduced
  • Contact Harald directly
Join to view full profile

Other similar profiles

Explore more posts

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More

Add new skills with these courses

See all courses